Savara (SVRA) Operating Expenses (2010 - 2026)
Savara (SVRA) posted quarterly Operating Expenses of $39.0 million for Q1 2026, up 37.12% year-over-year from $28.4 million in Q1 2025, and up 16.67% quarter-over-quarter from $33.4 million in Q4 2025.
Savara (SVRA) Operating Expenses (2010 - 2026) Analysis & Trends
Savara (SVRA) has reported Operating Expenses for 17 consecutive years, with $39.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 37.12% year-over-year to $39.0 million; the TTM figure through Mar 2026 stood at $134.1 million (up 22.86% YoY), while the FY2025 annual figure was $123.5 million, up 19.72% from the prior year.
- Operating Expenses grew to $39.0 million in Q1 2026 per SVRA's latest filing, from $33.4 million in the prior quarter.
- Across five years, Operating Expenses topped out at $39.0 million in Q1 2026 and bottomed at $8.0 million in Q1 2022.
- Historically, Operating Expenses has averaged $21.4 million across 5 years, with a median of $22.5 million in 2024.
- Annual changes were most pronounced in 2022 — Operating Expenses fell 22.74% — and 2024, when it surged 89.76%.
- Savara's Operating Expenses stood at $10.9 million in 2022, then jumped by 62.11% to $17.6 million in 2023, then jumped by 76.82% to $31.2 million in 2024, then climbed by 7.2% to $33.4 million in 2025, then climbed by 16.67% to $39.0 million in 2026.
- Business Quant data shows SVRA's Operating Expenses at $39.0 million in Q1 2026, $33.4 million in Q4 2025, and $30.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Savara | 1.11 Bn | 1.11 Bn | - | 40.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 40.97 Mn |
| Mar 31, 2026 | 38.99 Mn |
| Dec 31, 2025 | 33.42 Mn |
| Sep 30, 2025 | 30.26 Mn |
| Jun 30, 2025 | 31.44 Mn |
| Mar 31, 2025 | 28.44 Mn |
| Dec 31, 2024 | 31.17 Mn |
| Sep 30, 2024 | 26.36 Mn |
| Jun 30, 2024 | 23.19 Mn |
| Mar 31, 2024 | 22.48 Mn |
| Dec 31, 2023 | 17.63 Mn |
| Sep 30, 2023 | 18.04 Mn |
| Jun 30, 2023 | 12.22 Mn |
| Mar 31, 2023 | 12.11 Mn |
| Dec 31, 2022 | 10.88 Mn |
| Sep 30, 2022 | 10.54 Mn |
| Jun 30, 2022 | 9.38 Mn |
| Mar 31, 2022 | 8.05 Mn |
| Dec 31, 2021 | 10.64 Mn |
| Sep 30, 2021 | 9.97 Mn |